Presentations and Interviews

  Presentation Media Date

Martin Jönsson presented at Life Science Investor Conference the company’s successes and ongoing projects, as well as the company’s new share issue.

November 23, 2022

CEO Martin Jönsson presents AlzeCure’s progress and ongoing projects, as well as the company’s proposed share issue. (English)

November 17, 2022

Aktiespararna’s event with AlzeCure on November 16, 2022 – Martin Jönsson, AlzeCure’s CEO, presented the company’s progress and ongoing projects, as well as the company’s planned share issue. The presentation was held in Swedish.

November 16, 2022

CEO Martin Jönsson presented the company’s latest developments at Redeye Theme: Neurology on October 12, 2022

October 12, 2022

CEO Martin Jönsson presented an update on our Pain management projects at Redeye Theme: Neurology on October 12.

October 12, 2022

The Trk-PAM ACD856 improves mitochondrial function and increases BDNF levels in primary cortical neurons; Scientific presentation at the ISMND Conference, Athens, October 10-12, 2022

October 11, 2022

Analgesic and Anti-inflammatory Effects of Small Molecule Negative Allosteric Modulators of TrkA; Scientific presentation at the IASP Conference, Toronto, September 19-23, 2022

September 22, 2022

Martin talks about the latest developments for AlzeCure including the phase 2 study with ACD 440 against neuropathic pain, the new positive clinical results with NeuroRestore ACD 856, our new patent and the new results with the pain project TrkA-NAM. (Swedish)

September 12, 2022

Interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the latest clinical progress (Swedish)

September 1, 2022

Results From a Multiple Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors AAIC July – Aug 2022

July 31, 2022

Watch the interview with Aktiespararna at Finwire with AlzeCure’s CEO Martin Jönsson. (Swedish)

July 1, 2022

AlzeCure – Interview at Redeye with CEO Martin Jönsson about the phase II study with ACD440. (Swedish)

June 23, 2022

AlzeCure at Redeye Growth Day

June 2, 2022

CEO Martin Jönsson Presenting at Redeye Growth Day

May 23, 2022

The use of PathHunter cell lines to discover modulators of Trk-receptors. From HTS to phase 1; Scientific presentation at the ELRIG Conference, Gothenburg, May 10-12, 2022

May 10, 2022

AlzeCure – Alzheimer event at Redeye (Swedish)

3 May, 2022

Identification of a positive modulator of neurotrophin recptors with memory-enhancing effects and improved mitochondrial function; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research

April 21, 2022

Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm

April 21, 2022

Preliminary Results From a Single Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm,

April 21, 2022

A positive modulator of neurotrophin receptors improves cognition and mitochondrial function; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022

March 17, 2022

NeuroRestore – Preliminary results from a Single Ascending Dose study in healthy volunteers of ACD856, a positive modulator of Neurotrophin Trk-receptors; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022

March 15, 2022

Watch the Analysisguide’s interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the future. (in Swedish)

March 14, 2022

CEO Martin Jönsson is interview by BioStock on the company’s latest developments, including the ongoing rights issue.

March 14, 2022

CSO Johan Sandin explains the science behind AlzeCure’s project portfolio and what distinguishes it from other pharma companies. (Swedish)

March 14, 2022

See CEO Martin Jönsson and CSO Johan Sandin, present upcoming events in the company and the ongoing issue. (Swedish)

March 11, 2022

Watch the interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the ongoing issue. (Swedish)

March 9, 2022

AlzeCure – New presentation at Penser (Swedish)

February 24, 2022

Latest newsflow (Swedish)

February 3. 2022

CEO Martin Jönsson presents at Aktiespararna (Swedish)

January 31, 2022

Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease. (Text only)

January 27, 2022

Alzstatin – Development of novel γ-secretase modulators for the treatment of Alzheimer’s disease.

January 27, 2022

Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease, Scientific presentation at 11th Pharmaceutical Profiling meeting, January 27, 2022

January 27, 2022

AlzeCure Pharma – Kapitalmarknadsdag

January 18, 2022

AlzeCure medverkar på Erik Penser Banks temadag Life Science december 2, 2021 (Swedish)

December 2, 2021

Follow us – Stay updated

November 22, 2021

AlzeCure Pharma – Redeye Life Science Day

November 11, 2021

AlzeCure update on the latest developments – Interview with CEO Martin Jönsson about the company, its projects developments in Alzheimer’s and pain, and future plans.

October 22, 2021

Alzecure presents at Healthcare Innovation Summit

October 7, 2021

Alzecure Pharma – Naventus Life Science Summit

September 29, 2021

Aktiespararna interview CEO Martin Jönsson – latest quarterly report and future prospects. (Swedish)

September 20, 2021

AlzeCure Pharma – Aktiedagen Stockholm. (Swedish)

September 7, 2021

Alzheimer’s disease and the neurotrophins BDNF/NGF by Prof. Maria Eriksdotter M.D., PhD

September 1, 2021

Strategy Update on Alzheimer’s Disease & NeuroRestore

September 1, 2021

Company Overview & Vision by Martin Jönsson CEO

September 1, 2021

NeuroRestore Background and evolution by Dr Pontus Forsell, PhD Head of Discovery & Research

September 1, 2021

Development plan for NeuroRestore ACD856 by Dr Johan Sandin, PhD Chief Scientific Officer

September 1, 2021

ACD856 – a novel positive allosteric modulator of Trk-receptors in clinical development for the treatment of Alzheimer’s disease; Scientific presentation at AAIC, July 26-30, 2021

July 29, 2021

About Alzstatin and drugs for Alzheimer’s disease – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)

June 11, 2021

About suffering from Alzheimer’s disease, diagnostics, care today and future needs – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)

June 11, 2021

Negative Allosteric Modulators of TrkA for the Treatment of Pain – Scientific presentation at the IASP conference on pain, June 2021

June 11, 2021

About AlzeCure’s origin and development – An embryo that can be something big – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)

June 11, 2021

ACD440 – A Novel TRPV1 Antagonist for the Topical Treatment in Neuropathic Pain – Scientific presentation at the IASP conference on pain, June 2021

June 9, 2021

Alzecure: CEO Martin Jönsson present at Redeye Growth Day

June 7, 2021

CEO presentation at the annual meeting (Swedish)

May 20, 2021

CEO Martin Jönsson after the company’s annual meeting

May 17, 2021

TrkA- NAM – Project in osteoarthritis & other severe pain conditions by Head of Discovery & Research Pontus Forsell, May 11, 2021

May 11, 2021

ACD 440 – A novel VR1 antagonist for neuropathic pain by CSO Johan Sandin, May 11, 2021

May 11, 2021

Chronic Pain – a high unmet medical need by CMO Märta Segerdahl, May 11, 2021

May 11, 2021

Company overview and goals by CEO Martin Jönsson, May 11, 2021

May 11, 2021

Update on Progress in the Painless Platform, May 11, 2021

May 11, 2021

Alzecure: Interview with CEO Martin Jönsson and CSO Johan Sandin (video)

April 20, 2021

Alzecure: Interview with CEOMartin Jönsson (video). (Swedish)

March 1, 2021

Interview with Martin Jönsson CEO in Aktiespararna’s analysis guide

February 8, 2021

CEO Martin Jönsson presentation, Aktiedagen Lund

January 27, 2021

Interview with Johan Sandin (CSO) in Aktiespararna’s analysis guide

January 22, 2021

Improving Quality of Life for People with Neurodegenerative Diseases – Stockholm Researchers and Health Tech Companies

January 14, 2021

Alzecure: CEO Martin Jönsson presents at Redeye Life Science Day 2020

December 1, 2020

Scientific and market update with professor Henrik Zetterberg on Alzheimer’s disease, bio-markers, potential future treatments, including Alzstatin and AlzeCure

September 30, 2020

AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish)

September 8, 2020

AlzeCure Science & Market update about Alzheimer’s diseas and NeuroRestore (Swedish)

September 1, 2020

Get to know AlzeCure’s CEO Martin Jönsson – Redeye interview (Swedish)

March 19, 2020

AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish)

March 16, 2020

About Alzheimers disease

February 27, 2018

About the project NeuroRestore®, symptomatic treatment of cognitive disorders such as in Alzheimer’s disease

February 27, 2018

Welcome to AlzeCure … Introduction film about the company (Swedish) – 1 minute

Scientific presentation about ACD856, a positive modulator of neurotrophin signaling reverses scopolamine- or age-induced cognitive deficits

April 2-5, 2020

Scientific presentation on Alzstatin presented at the CTAD conference

November 4-7, 2020

Scientific presentation on the NeuroRestore® candidate ACD856 presented at the CTAD conference

November 4-7, 2020

About the Alzstatin® project Disease modifying treatment of Alzheimer’s disease

Gamma-secretase modulation results in multiple anti-amyloidogenic effects in vivo; Scientific presentation at the AAT-AD/PD conference, Italy, March 15-18, 2018

March 15-18, 2018

Characterization of positive allosteric modulators of TrkB for the treatment of depression

October 2-5, 2021